Person Communication and Meetings / Product Issues / FDA Phase / / /
IndustryTerm
supply chain / illegitimate products / drug supply chain / pharmaceutical distribution chain / anti-counterfeiting technologies / wholesale distributor / transacted business involving suspect products / suspect products / illegitimate product / law enforcement / pharmaceutical distribution supply chain / suspect product / /
MedicalCondition
HIV / cancer / /
Organization
U.S. Department of Health and Human Services / CDER office of Compliance / office of Communication / Outreach and Development / Food and Drug Administration Center for Drug Evaluation and Research / Food and Drug Administration / office of Compliance / office of Regulatory Affairs / office of Communication / Food and Drug Administration Center for Drug Evaluation / U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research / first FDA Counterfeit Drug Task Force / Congress / Division of Dockets Management / Drug Supply Chain Security Act / office of Communications Division of Drug Information / Center for Biologics Evaluation and Research / Center for Biologics Evaluation and Research Food and Drug Administration / /
Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification